Acute lymphoid leukemia etiopathogenesis.

Acute lymphoid leukemia (ALL) is a type of hematological neoplasm that affects the precursor cells of strains B, T  and NK, with a higher incidence in the pediatric range. The pathophysiology of ALL is characterized by chromosomal abnormalities and genetic alterations involved in the differentiation and proliferation of lymphoid precursor cells. Despite the lack of information in the literature, it is believed that leukemogenesis originates from a complex interaction between environmental and genetic factors, which combined lead to cellular modifications. Environmental factors have been evaluated as possible predisposing factors in the development of ALL but there are still conflicting results in the world literature. In this context, the aim of the present review is to discuss the major exogenous factors regarding ALL.

Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen.

The WT1 gene encodes a transcription factor involved in regulation of many cellular processes, including proliferation, differentiation, mRNA processing and apoptosis, besides acting as a transcription repressor of growth factors and their receptors' genes. This gene is expressed at high levels in several types of cancers, including acute leukemias. In this regard, many studies have identified WT1 protein as a tumor antigen, considered a target molecule for clinical application in human acute leukemias. Immunotherapy using WT1 antigen has been effective in stimulating immune responses against leukemic cells. Regarding adoptive immunotherapy, the use of dendritic cells (DCs) for the WT1-specific cytotoxic T cells generation proved to be efficient in the development and maintenance of immunologic cells. Therefore, these therapeutic methods, that provided enthusiasm for moving ahead, highlight several opportunities and challenges to be used in clinical practice for managing acute leukemias.

Role of CXCL12 and CXCR4 in normal cerebellar development and medulloblastoma.

Chemokines and its receptors have significant impact on physiological and pathological processes and studies concerning their association with tumor biology are subject of great interest in scientific community. CXCL12/CXCR4 axis has been widely studied due to its significant role in tumor microenvironment, but it is also important to development and maintenance of tissues and organs, for example, in the brain and cerebellum. Studies have demonstrated that CXCL12 and CXCR4 are required for normal cerebellar development and that dysfunction in this pathway may be involved with medulloblastoma pathogenesis. In this context, a new molecular subgroup has been suggested based on the importance of the association between CXCR4 overexpression and sonic hedgehog subgroup. Treatment using CXCR4 antagonists showed significant results, evidencing the important role and possible therapeutic capacity of CXCR4 in MB. This review summarizes studies on MB cell biology, focusing on a chemokine-receptor axis, CXCL12/CXCR4, that may have implications for treatment strategies once it can improve life expectancy and reduce neurocognitive sequelae of patients with this neoplasia.

Análise dos efeitos da epigalocatequina-3-galato (EGCG) de Camelliasinensis (chá verde) em modelo de hepatotoxicidade químicaexperimental induzida pela Dietilnitrosamina (DEN) / Analysis of the effects of epigallocatechin-3-gallate (EGCG) of Camellia sinensis (green tea) in experimental chemical model of hepatotoxicity induced by Diethylnitrosamine (DEN)

A Dietilnitrosamina (DEN), uma substância reconhecidamente hepatotóxica e carcinogênica, foiutilizada na indução da necrose hepática centrolobular em ratos isogênicos Lewis divididos em 5 grupos de 5 animais. O objetivo deste estudo foi avaliar o efeito quimiopreventivo da epigalocatequina-3-galato (EGCG), de Camellia sinensis (chá verde) no tratamento da hepatotoxicidade celular induzida pela DEN. Foi mensurada a concentração sérica da alanina aminotransferase (ALT) e aspartato aminotransferase(AST) dos diferentes grupos experimentais. No ensaio bioquímico para AST e ALT, houve diferença significativa entre os valores médios do grupo controle (163±70,32) comparado ao grupo DEN (1631±1039,44), sugerindo que a DEN influencia na função hepática. Entretanto, não houve diferença significativa entre o grupo DEN e o tratado com epigalocatequina. A lactato desidrogenase (LDH) éconsiderada um marcador bioquímico comum para avaliação da progressão tumoral, e em relação ao LDH, as amostras não apresentaram diferenças significativas entre o grupo DEN (1385,5±43,13) e DEN + EGCG 150mg ou DEN + EGCG 200mg 1537,5±1010,45). Neste trabalho foi demonstrado que a epigalocatequina nas concentrações de 150 e 200 mg/Kg não induziram alterações hepáticas e também não foi possível verificar nenhuma quimioproteção pela EGCG em animais inicialmente tratados comDEN durante 24 horas. Sendo assim, novos experimentos com diferentes concentrações de EGCG sãonecessários para comprovar seu possível efeito quimioprotetor.

Diethylnitrosamine (DEN), a known hepatotoxic and carcinogenic substance, was used in the induction of centrilobular hepatic necrosis in isogenic Lewis rats divided into 5 groups with 5 animals. The aim of this study was to evaluate the chemopreventive effect of epigallocatechin-3-gallate (EGCG)from Camellia sinensis (green tea) in the treatment of cellular hepatotoxicity induced by DEN. It was measured the serum concentration of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of the different experimental groups. In the biochemistry assay for AST and ALT, there was significant difference between median values of control group (163±70.32) compared to DEN group(1631±1039.44), suggesting that DEN influences on hepatic function. However, there was no significant difference between DEN group to that treated with epigallocatechin. Lactate dehydrogenase (LDH) is considered a common biochemical marker for evaluation of tumor progression, and regarding LDH,the samples presented no significant differences between the DEN group (1385.5±43.13) and DEN + EGCG 150mg or DEN + EGCG 200mg (1537.5± 1010.45). In this work it was demonstrated that epigallocatechin concentrations of 150 and 200 mg/kg did not induce liver alterations and though was not verified any chemoprotective effect by EGCG in animals initially treated with DEN for 24 hours. Moreover, new experiments with different concentrations of EGCG are needed to verify its possiblechemoprotector effect.

Detection of Lsr2 gene of Mycobacterium leprae in nasal mucus

In the present study, nasal mucus from patients with leprosy were analyzed by PCR using specific primers for Lsr2 gene of Mycobacterium leprae. The presence of Lsr2 gene in the nasal mucus was detected in 25.80% of patients with paucibacillari leprosy, and 23.07% of contacts. Despite the absence of clinical features in the contact individuals, it was possible to detect the presence of Lsr2 gene in the nasal mucus of these individuals. Therefore, PCR detection of M. leprae targeting Lsr2 gene using nasal mucus samples could contribute to early diagnosis of leprosy.

Ação do extrato de própolis na Leishmaniose / Propolis extract action in Leishmaniasis

A leishmaniose causa mortalidade e morbidade em mais de 80 países e caracteriza-se como uma doença parasitária com diversas manifestações, por isso constitui um sério problema de saúde pública. No Novo Mundo ocorre a Leishmaniose Visceral (LV) e Leishmaniose Tegumentar Americana (LTA). A LTA é considerada uma enfermidade polimórfica, espectral da pele e das mucosas, agrupada em diferentes formas clínicas: a leishmaniose cutânea, a cutaneomucosa e a cutânea difusa. A Organização Mundial da Saúde recomenda os antimoniais pentavalentes como drogas de primeira escolha no tratamento da leishmaniose. Entretanto, devido aos efeitos indesejados dessas drogas, tem sido proposto o estudo para o desenvolvimento de novos fármacos para seu tratamento. Assim, tem-se investigado o uso da própolis, visto que está relacionada a muitas atividades biológicas, como antibacteriana, antifúngica, antiulcerativa, antiviral, antiprotozoária, antiinflamatória, hepatoprotetora, antioxidante, antitumoral, entre outras. Estudos recentes mostraram que a própolis verde ativa macrófagos e estimula os linfócitos B a produzirem anticorpos. A própolis tem demonstrado potencial atividade leishmanicida, por diminuir o diâmetro das lesões, causar alterações morfológicas nas formas promastigotas ou ainda por melhorar a resposta imunológica frente às Leishmanias, ativando macrófagos.Portanto, o objetivo deste trabalho foi relatar as principais atividades leishmanicidas da própolis, por meio de pesquisa bibliográfica eletrônica no PubMed e Scielo durante o ano de 2009. .

Leishmaniasis is a public health problem causing morbidity and mortality in over 80 countries and features a parasitic disease with several manifestations. In the New World occur Visceral Leishmaniasis (VL) and American Cutaneous Leishmaniasis (ACL). The ACL is considered a disease polymorphic of skin and mucous membranes, grouped in different clinical forms: cutaneous leishmaniasis in the skin and mucosa and diffuse cutaneous, and the evolution of this disease is closely related to the mechanisms of escape of the protozoan Leishmania from the immune response, allowing the development of the disease and consequently the onset of clinical manifestations known. The World Health Organization recommends the pentavalent antimony as the first choice drugs. However, they usually give unsatisfactory results, requiring the development of new and affordable drugs for its treatment. It has been investigated that use of propolis it is related to exhibit several biological activities such as antibacterial, antifungal,anti-ulcer agents, antiviral, anti-protozoan, anti-inflammatory, hepatoprotective, antioxidant, antitumor, among others. Recent studies have shown that green propolis active macrophages and stimulates lymphocytes B to produce antibodies. It was also reported that propolis shows a potential antileishmanial activity by reducing the diameter of the lesions, avoiding complications of the lesions by bacteria or by improving the immune response against the Leishmania through macrophages activation. The aim of this work was related the main activities leishmanicida using propolis, by searched the electronic literature PubMed and Scielo during the year 2009..

Envolvimento das quimiocinas CCL2 e CCL5 na patogênese do câncer de mama / Involvement of CCL2 and CCLS chemokines in breast cancer pathogenesis

No Brasil, o câncer de mama é o que mais causa mortes entre as mulheres com um risco de 51 casos a cada 100 mil mulheres. A metástase, principal causa de morte pelo câncer de mama, e dirigida a urna variedade de órgaos vitais, como ossos, pulmões, cerebra e fígado. Ocorre quando células tumorais geneticamente instáveis adaptam-se ao microambiente do tecido que esta distante do tumor primário. A natureza heterogênea da metástase no câncer de mama dificulta não apenas a cura, mas também a estimativa dos fatores de risco. A disseminação das células tumorais é realizada através da circulação sanguínea sistêmica atingindo outros órgãos. Tern sido verificado que essas células utilizam-se da expressão dos receptores de quimiocinas, para encontrar órgaos alvo que produzem um particular conjunto de quimiocinas. Mais recentemente, foi estabelecido que as células do câncer aproveitam-se da sinalização através dos receptores para quimiocinas para a iniciação e progressão do tumor primário e da metástase. Embora grande número de moléculas tenha sido implicada na metástase do câncer de mama, o mecanismo exato que determina a direção da migração parece incerto. Tem sido demonstrado que CCL2 e CCL5 estão expressas em grande quantidade pelas células tumorais do câncer de mama e são a causa da malignidade e metástase neste órgão. A expressão dessas duas quimiocinas pelas células do tumor de mama acompanha eventos de transformação maligna, e está associada com o curso avançado e progressão da doença. Desse modo, vários estudos sugerem que a determinação e o prognóstico das quimiocinas CCL2 e CCL5 será de grande para uma melhor identificação do risco de progressão e determinação das implicações terapêuuticas em pacientes com câncer de mama.

In Brazil, breast cancer is the major cause death among women with a risk of 51 cases to 100 thousand women. The metastasis, the main cause of death by breast cancer, is directed to a variety of vital organs such as bones, lungs, brain and liver. Occurs when genetically unstable tumor cells adapt to the microenvironment of the tissue that is distant from the primary tumor. The heterogeneous nature of metastasis in breast cancer is difficult not only for the definition of cure for this disease, but also to estimate their risk factors. The spread of tumor cells is achieved through the systemic bloodstream to reach other organs. It has been verified that these cells are used the expression of chemokine receptors to find on target organs that produce a particular set of chemokines. It was established that the cancer cells use the signaling through the receptors for chemokines in the initiation and progression of primary tumor and metastasis. Although large number of molecules has been implicated in metastasis of breast cancer, the exact mechanism that determines the direction of migration seems uncertain. In a review conducted recently, the authors argue that CCL2 and CCL5 are expressed in large amounts by tumor cells of breast cancer and are the cause of malignancy and metastasis in this organ. The expression of these chemokines by the tumor cells of breast accompanying events of malignant transformation, and is associated with the advanced course and progression of disease. Thus several studies suggest that the determination and validation of the prognostic value of the chemokines CCL2 and CCL5 will be of great value for better identification of risk of progression and determine the therapeutic implications in patients with breast cancer.

Determinação da lactate desidrogenase (LDH) e do transcrito Bcr-Abl em pacientes com leucemia mielóide crônica / Determination of lactate dehydrogenase (LDH) and Bcr-Abl transcript in the follow-up of patients with chronic myeloid leukemia

Leucemia mieloide crônica (LMC) é uma desordem mieloproliferativa maligna que é originada de célula-tronco pluripotente caracterizada por expansão anormal, maligna de clones de células tronco da medula óssea na circulação. A grande maioria dos pacientes com LMC apresentam transcritos Bcr-Abl. Lactato desidrogenase (LDH), considerado um marcador bioquímico para crescimento tumoral, glicólise anaeróbica, e tem sido considerado um fator de pior prognóstico da LMC. Portanto, este estudo visa avaliar a concentração de LDH no plasma e a detecção do transcrito Bcr-Abl em 22 pacientes com LMC e 56 indivíduos saudáveis. Foram avaliados 22 pacientes com LMC e 56 doadores saudáveis. A concentração de LDH no plasma foi maior nos pacientes com LMC. Todos pacientes com LMC neste estudo estavam em tratamento, mesmo assim quatro pacientes apresentavam o transcrito Bcr-Abl (b3a2) no sangue periférico. Dois dos quatro pacientes com o transcrito b3a2 apresentavam LDH elevado (486 U L-1 e 589 U L-1). Embora o estudo tenha sido realizado com um pequeno número de amostras, é possível sugerir alteração de terapia para os dois pacientes que apresentam o transcrito b3a2 na amostra de sangue periférico com concentração de LDH elevada.

Chronic myeloid leukemia (CML) is a malignant myeloproliferative disorder that originates from a pluripotent stem cell characterized by abnormal release of the expanded, malignant stem cell clone from the bone marrow into the bloodstream. The vast majority of patients with CML present Bcr-Abl transcripts. Lactate dehydrogenase (LDH) is considered a biochemical marker common for tumor growth, anaerobic glycolysis and has been considered a poor prognostic factor for acute myeloid leukemia. Therefore, this study aimed to evaluate the concentration of LDH in plasma and the detection of the Bcr-Abl transcripts in patients with CML and healthy donors. We analyzed 22 patients demonstrably diagnosed with CML and 56 healthy donors. LDH concentration in plasma was higher in patients with CML. All patients with CML in this study were under treatment, but even so four patients had the Bcr-Abl (b3a2) transcript in peripheral blood. Two out of the four patients with b3a2 showed higher LDH (486 U L-1 and 589 U L-1). Thus, although the study was conducted with small numbers of samples, it is possible to suggest therapy alteration for two patients who presented transcript b3a2 in the peripheral blood samples and whose LDH concentration was high, in order to improve the disease

CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Chemokines and their receptors regulate the trafficking of immune cells during their development, inflammation, and tissue repair. The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/ stromal cell-derived factor-1 (SDF1)-3'A) in CXCL12/SDF1 gene was assessed in breast cancer, Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL), since the chemokine CXCL12, previously known as SDF1, and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis, and metastasis of different types of tumors. Genotyping was performed by PCR-RFLP (polymerase chain reaction followed by restriction fragment length polymorphism) using a restriction enzyme HpaII cleavage. No significant difference was observed in genotype distribution between breast cancer patients (GG: 57.3%; GA: 39.8%; AA: 2.9%) and healthy female controls (GG: 62.9%; GA: 33%; AA: 4.1%) nor between HL patients (GG: 61.1%; GA:27.8%; AA: 11.1%) and healthy controls (GG: 65.6%; GA: 28.9%; AA: 5.5%), whereas a significant difference was observed in genotype distribution between NHL patients (GG: 51.4%; GA: 47.1%; AA: 1.5%) and healthy controls (GG: 65.6%; GA: 28.9%; AA: 5.5%). Further studies will be necessary to elucidate the cancer chemokine network. However, this study suggests that CXCL12 rs1801157 polymorphism may have important implications in the pathogenesis of NHL.